Cancer immunotherapy by immune checkpoint blockade has proven its great potential by
saving the lives of a proportion of late stage patients with immunogenic tumor types …

Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is
notoriously resistant to immunotherapy mainly due to its unique immune microenvironment …

Autoimmune diseases are the third most common disease influencing the quality of life of
many patients. Here, a programmed cell death‐ligand 1+(PD‐L1) mesenchymal stem cell …

Abstract N6-methyladenosine (m6A) modification plays important roles in various cellular
responses by regulating mRNA biology. However, how m6A modification is involved in …

Objective Solid tumours respond poorly to immune checkpoint inhibitor (ICI) therapies. One
major therapeutic obstacle is the immunosuppressive tumour microenvironment (TME) …

CNS immune defenses are marshaled and dominated by brain resident macrophages and
microglia, which are the innate immune sentinels and frontline host immune barriers against …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …

The invasiveness and high immune suppression of glioblastoma multiforme (GBM) produce
poor survival of afflicted patients. Unfortunately, in the past decades, no therapeutic …

How cancer cells evade the therapeutic effects of immune checkpoint blockade is largely
unknown. Here, we report that fibrinogen-like protein 1 (FGL1), a newly identified immune …

Brain cancers carry bleak prognoses, with therapeutic advances helping only a minority of
patients over the past decade. The brain tumour microenvironment (TME) is highly …